Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen novartis Collaboration (Aimovig) — Profit Share in Cost of Sales (legacy) ($M) ($M)
Form 10-K Collaborations Note (XBRL)
Latest, FY2021
116
Period ended Dec 31, 2021
Change on a year earlier
-16.5%
139 in FY2020
History
4 years
Since FY2018
Sources
4
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Novartis Collaboration (Aimovig) — Profit Share in Cost of Sales (legacy) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2021 | Dec 31, 2021 | 116 | -16.5% | Form 10-K (filed 2024-02-14) ↗ |
| FY2020 | Dec 31, 2020 | 139 | +20.9% | Form 10-K (filed 2023-02-09) ↗ |
| FY2019 | Dec 31, 2019 | 115 | +167.4% | Form 10-K (filed 2022-02-16) ↗ |
| FY2018 | Dec 31, 2018 | 43 | – | Form 10-K (filed 2021-02-09) ↗ |
Breakdown
What makes up novartis collaboration (aimovig) — profit share in cost of sales (legacy) ($m)
Cite this data
StockData. (2026). Amgen Novartis Collaboration (Aimovig) — Profit Share in Cost of Sales (legacy) ($M) ($M), annual FY2018–FY2021 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/collab_novartis_cos
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.